MAP2K5

Across TCGA pan-cancer cohorts, MAP2K5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAP2K5 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MAP2K5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP2K5 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

ESCA, BLCA, and UCEC are the cancer types where MAP2K5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.164	0.702	.001	33	view →
BLCA	DFS	Median	All	1.000	0.503	.016	10	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	OS	Median	All	0.519	0.752	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAP2K5–ESCA (OS)

Open the ESCA breakdown →